Lighthouse Investment Partners LLC Sells 19,327 Shares of DexCom, Inc. (NASDAQ:DXCM)

Lighthouse Investment Partners LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 47.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 21,773 shares of the medical device company's stock after selling 19,327 shares during the quarter. Lighthouse Investment Partners LLC's holdings in DexCom were worth $1,693,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of DXCM. Private Trust Co. NA grew its stake in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares during the period. Optiver Holding B.V. bought a new position in DexCom in the 4th quarter valued at $33,000. TD Private Client Wealth LLC grew its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC grew its stake in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC bought a new position in DexCom in the 4th quarter valued at $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on DXCM. Piper Sandler reduced their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Robert W. Baird reduced their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and increased their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Mizuho began coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has an average rating of "Moderate Buy" and a consensus target price of $98.11.

DexCom Price Performance

Shares of NASDAQ:DXCM traded down $0.19 on Friday, hitting $85.48. The company's stock had a trading volume of 3,397,377 shares, compared to its average volume of 4,356,519. The company has a 50-day simple moving average of $72.01 and a 200 day simple moving average of $77.60. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $132.26. The company has a market capitalization of $33.52 billion, a PE ratio of 59.78, a PEG ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the previous year, the business earned $0.32 EPS. The business's revenue was up 12.5% on a year-over-year basis. Sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, EVP Jereme M. Sylvain sold 7,000 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares of the company's stock, valued at approximately $10,002,636.06. This trade represents a 4.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Michael Jon Brown sold 13,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. This represents a 10.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 in the last 90 days. Corporate insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.